/ /

CLINICAL

Ebola may leave retinal scarThe Ebola virus may leave a retinal scar specific to the disease, according to researchers. “The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile virus,” said Dr Paul Steptoe of the Royal Liverpool Hospital, in a press release.
ODs must embrace new technologies, says AOA panelDisruptive technology is here to stay, and ODs must embrace it as new technologies continue to be developed and patients are eager to get their hands on them.
Understanding the role of inflammation in dry eyeOptometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.
10 tips to enhance scleral contact lens successImprove your scleral fitting skills and your patients’ quality of life
Glaucoma monitoring implant receives CE markAn implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
How tear proteomics can help optometryODs undervalue ocular point-of-care tear testing
Pearls from BCLA 2017: CLIDE and blepharitis
Pearls from BCLA 2017: CLIDE and blepharitisThe British Contact Lens Association (BCLA) celebrated its 40th birthday June 9-11 at its 2017 clinical conference and exhibition in Liverpool, UK. Optometry Times was there to hear the latest and live tweet from the meeting.
Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseasesThe gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.